Cervical cancer
- Study type
- Review article
- Design
- Review article
- Sample size
- Not applicable (review article)
- Source
- The Lancet · 2019
In plain words
Cervical cancer is mostly caused by infection with high-risk types of the HPV virus and can largely be prevented. Regular screening and HPV vaccination play an important part in reducing how often it occurs and how many people die from it. Depending on how far the disease has spread, treatment includes surgery, chemoradiotherapy or both, and in early, low-risk cases methods that preserve fertility can be chosen. In advanced or recurrent disease, drugs such as bevacizumab have helped improve results, and new immunotherapy approaches are promising.
Key results
Study population
This is a review article and no patients were enrolled. The article covers cervical cancer in women at different stages of the disease (early, locally advanced, metastatic or recurrent).
Endpoints
Not applicable; this is a review article and no primary or secondary endpoints were defined.
Safety and side effects
The abstract reports no specific figures for adverse events (grade 3 and above). It only notes that advances in radiotherapy technology, such as intensity-modulated radiotherapy (IMRT), have reduced treatment-related toxicity in women with locally advanced disease.
Clinical significance and place in guidelines
This review gives an overview of the global burden of the disease, the role of screening and HPV vaccination, and treatment approaches. Based on the abstract, fertility-sparing surgery has become the standard treatment for low-risk early disease, intensity-modulated radiotherapy has reduced toxicity in locally advanced disease, and bevacizumab has extended overall survival beyond 12 months in metastatic or recurrent disease. The status of formal clinical guideline recommendations and drug approvals should be checked separately.
Limitations
This is a narrative review and presents no primary data or new statistical analysis. Details of the literature search and study selection criteria are not given in the abstract. Immunotherapy findings were only preliminary at the time of publication (2019).
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.